Expertise in
8
conditions

Jitao Y. Wu

NO. 20 East Yuhuangding Road, 
Yantai, CN 
Expertise in
8
conditions
NO. 20 East Yuhuangding Road, 
Yantai, CN 

Overview

Jitao Wu practices practicing medicine in Yantai, China.

Wu is highly rated in 8 conditions, according to our data. Their clinical expertise encompasses Renal Cell Carcinoma (RCC), Erectile Dysfunction (ED), Peyronie Disease, Nephrectomy, and Lithotripsy.

They are actively involved in clinical research, co-authoring 217 peer reviewed articles and participating in 2 clinical trials.

Locations

NO. 20 East Yuhuangding Road, Yantai, 264000, China
Other Locations
NO. 20 East Yuhuangding Road, Yantai, China
28 Fuxing RD, Haidian, 100853, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

217 Total Publications

POU2F2 as a dual oncogenic and immunomodulatory driver in kidney renal clear cell carcinoma.
POU2F2 as a dual oncogenic and immunomodulatory driver in kidney renal clear cell carcinoma.
Journal: Cell adhesion & migration
Published: July 09, 2026

Frequently Asked Questions about Jitao Y. Wu

Is Jitao Y. Wu a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Jitao Y. Wu is classified as an Distinguished expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jitao Y. Wu participate in research or clinical trials?

Yes. Jitao Y. Wu has published 217 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Jitao Y. Wu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wu's expertise for a condition
ConditionClose
    View All 42 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile